RTSN · Retension Pharmaceuticals, Inc. · Investor Relations
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-10-09 |
Retension Pharmaceuticals Announces Pricing of Initial Public Offering
FALLS CHURCH, Va., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, announced today the |
| 2026-09-14 |
Retension Pharmaceuticals Announces Formation of Scientific Advisory Board
Distinguished physicians and investigators in hypertension, cardiovascular diseases, nephrology and innovative cardiovascular trials to advise on the clinical development of RTN-001 FALLS CHURCH, Va.--( BUSINESS WIRE)-- Retension Pharmaceuticals, Inc. (“Retension” or the “Company”), a |
| 2026-09-10 |
Retension Pharmaceuticals Appoints LeAnne Bloedon, M.S., RD, as EVP of Clinical Development and Operations, and Kevin Schutz, PharmD, as VP Regulatory Affairs
Appointments strengthen clinical and regulatory leadership as the Company advances RTN-001 through its Phase 2b trial FALLS CHURCH, Va.--( BUSINESS WIRE)-- Retension Pharmaceuticals, Inc. (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for |
| 2026-05-27 |
Retension Pharmaceuticals Appoints Alison Schecter, M.D., as Chief Medical Officer and Alex Schwartz as Chief Financial Officer
Seasoned executives bring deep cardiovascular clinical development experience and financial leadership as RTN-001 advances through Phase 2b clinical testing FALLS CHURCH, Va.--( BUSINESS WIRE)-- Retension Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing RTN-001 for |
| 2025-08-06 |
Retension Pharmaceuticals Announces Completion of Series B Financing to Advance Phase 2b Trial for Uncontrolled and Resistant Hypertension and Issuance of a New U.S. Patent Covering its Lead Candidate, RTN-001
Retension Pharmaceuticals announces close of $15 Million Series B financing round Newly issued U.S. patent extends core intellectual property protection through at least 2044 Phase 2b study evaluating RTN-001 in patients with uncontrolled hypertension in collaboration with the Cleveland Clinic |
| 2024-08-21 |
Retension Pharmaceuticals Closes $10.4 Million Oversubscribed Series A to Fund Clinical Trials for Patients Suffering from Resistant and Uncontrolled Hypertension
FALLS CHURCH, Va.--( BUSINESS WIRE)-- Retension Pharmaceuticals, Inc. is pleased to announce the successful closing of its Series A $10.4 million financing round to initiate a well-powered and controlled Phase 2 clinical study in patients with hypertension uncontrolled on two or more |